Combined nicotinic and muscarinic blockade in elderly normal volunteers: Cognitive, behavioral, and physiologic responses

Neuropsychopharmacology

Volumn 19, Issue 1, 1998, Pages 60-69

  Little, John T ^a   Johnson, Douglas N ^c   Minichiello, Marcia ^a   Weingartner, Herb ^b   Sunderland, Trey ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c Center for Language and Brain   (United States)

Author keywords

Cognitive; Geriatrics; Mecamylamine; Muscarinic antagonist; Nicotinic antagonist; Scopolamine

Indexed keywords

MECAMYLAMINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; SCOPOLAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PULSE RATE; PUPIL; SYSTOLIC BLOOD PRESSURE;

EID: 0031749060     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00002-5     Document Type: Article

References (64)

1. Beatty WW, Butters N, Janowsky DS Patterns of memory failure after scopolamine treatment. Implications for cholingergic hypotheses of dementia Behav Neural Biol. 45:1986;196-211.
2. Borkowski JG, Benton AL, Spreen O Word fluency and brain damage. Neuropsychologia. 5:1967;135-140.
3. Bowen DM, Allen SJ, Benton JS, Goodhardt EA, Haan AM, Palmer NR, Sims NR, Smith CCT, Spillane JA, Esiri MM, Neary D, Snowdeon JS, Wilcock GK, Davison AN Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem. 41:1983;266-272.
4. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SV Muscarinic acetylcholine receptor subtypes. Localization and structure/function Prog Brain Res. 98:1993;121-127.
5. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM Modeling dementia. Effects of scopolamine on memory and attention Neuropsychologia. 16:1988;685-700.
6. Buschke H Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav. 12:1973;543-550.
7. Coyle JT, Price DL, DeLong MR Alzheimer's disease. A disorder of cortical cholinergic innervation Science. 219:1983;1184-1190.
8. Cozzolino R, Guaraldi D, Giuliani A, Chiradi O, Ramacci MT, Angelucci L Effects of concomitant nicotinic and muscarinic blockade on spatial memory disturbance in rats are purely additive. Evidence from the Morris water task Physiol Behav. 56:1994;111-114.
9. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol. 22:1987;229-236.
10. Davies P, Verth AH Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res. 138:1978;385-392.
11. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earn NL, Kumar V, Doody RS A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 327:1992;1253-1259.
12. Decker MW, Brioni JD, Bannon AW, Arneric SP Diversity of neuronal nicotinic acetylcholine receptors. Lessons from behavior and implications for CNS therapeutics Life Sci. 56:1995;545-570.
13. Dunne MP Scopolamine and sustained retrieval from semantic memory. J Psychopharmacol. 4:1990;13-18.
14. Elrod K, Buccafusco J Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther. 258:1991;403-409.
15. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J A controlled trial of tacrine in Alzheimer's disease. JAMA. 268:1992;2523-2529.
16. Flicker C, Serby M, Ferris SH Scopolamine effects on memory, language, visuospatial praxis, and psychomotor speed. Psychopharmacology. 100:1990;243-250.
17. 3H]nicotine binding in human cerebral cortex. Comparison between Alzheimer's disease and the normal J Neurochem. 47:1986;1948-1954.
18. Freis ED Mecamylamine in hypertension. Lancet. 2:1955;977.
19. Freis ED, Wilson IM Mecamylamine, a new orally effective, hypotensive agent. Arch Intern Med. 97:1956;551-561.
20. Friedland RP, Jagust WH, Huesman RH, Koss E, Knottel B, Mathis CA, Ober BA, Mazoyer BM, Budinger TF Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology. 39:1989;1427-1434.
21. Gitelman DR, Prohovnik I Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging. 13:1992;313-318.
22. Grober E, Sliwinski M Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol. 13:1991;933-949.
23. Haxby JV, Grady CL, Koss E, Horwitz B, Schapiro M, Friedland RP, Rapoport SI Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology. 38:1988;1853-1863.
24. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Res. 436:1987;62-68.
25. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 271:1994;985-991.
26. Kucera H, Francis WN Computational Analysis of Present-Day American English. 1967;Brown University Press, Providence, RI.
27. Kumar A, Schapiro MB, Grady C, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology. 4:1991;35-46.
28. 3H]methylcarbamycholine binding sites in the rat brain. J Neurochem. 52:1989;483-491.
29. Lapchak PA, Araujo DM, Quirion R, Collier B Presynaptic cholinergic mechanisms in the rat cerebellum. Evidence for nicotinic, but not muscarinic autoreceptors J Neurochem. 53:1989;1843-1851.
30. Levin ED Nicotinic systems and cognitive function. Psychopharmacology (Berl). 108:1992;417-431.
31. Levin ED, McGurk SR, South D, Butcher LL Effects of combined muscarinic and nicotinic blockade on choice accuracy in the radial-arm maze. Behav Neural Biol. 51:1989;270-277.
32. Levin ED, Rose JE, McGurk SR, Butcher LL Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol. 53:1990;103-112.
33. Martin BR, Onaivi ES, Martin TJ What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol. 38:1989;3391-3397.
34. Martin TJ, Suchocki J, May EL, Martin BR Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. J Pharmacol Exp Ther. 254:1990;45-51.
35. Mash DC, Flynn DD, Potter LT Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
36. Mattis S Mental status examination for organic mental syndrome in the elderly patient. Bellak L, Karasu TB Geriatric Psychiatry. 1976;77-121 Grune & Stratton, New York.
37. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev. 17:1992;215-226.
38. Moyer J, Heider C, Dennis E Mecamylamine (inversine) in the treatment of hypertension. JAMA. 164:1957;1879-1886.
39. Murphy DL, Mueller EA, Hill JL, Tolliver RJ, Jacobsen FM Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology. 98:1989;275-282.
40. Nebes RD Cognitive dysfunction in Alzheimer's disease. Craik FIM, Salthouse TA Handbook of Cognitive Aging. 1992;373-446 Lawrence Erlbaum Associates, Hillsdale, New Jersey.
41. Newhouse PA, Potter A, Corwin J, Lenox R Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology. 108:1992;480-484.
42. Newhouse PA, Potter A, Corwin J, Lenox R Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 10:1994;93-107.
43. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm. 2:1990;215-224.
44. Nordberg A, Alafuzoff I, Winblad B Nicotinic and muscarinic subtypes in the human brain. Changes with aging and dementia J Neurosci Res. 31:1992;103-111.
45. Overall JE, Beller SA The brief psychiatric rating scale (BPRS) in geropsychiatric research. I Factor structure on an inpatient unit. J Gerontol. 39:1984;187-193.
46. Overall JE, Gorham DR The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
47. Perry EK, Smith CJ, Court JA, Perry RH Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson, and Lewy body types. J Neural Transm. 2:1990;149-158.
48. Prohovnik I, Mayeux R, Sackheim HA, Smith G, Stern Y, Alderson PO Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology. 38:1988;931-937.
49. Riekkinen PJ, Sirvio J, Aaltonen M, Riekkinen P Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav. 37:1990;405-410.
50. Rogers SL, Friedhoff LT, and the Donepezil Study Group (1996): The efficacy and safety of donepezil in patients with Alzheimer's Disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7:293-303.
51. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H A potential noninvasive neurobiological test for Alzheimer's disease. Science. 266:1994;1051-1054.
52. Shimohama S, Taniguchi T, Fjuiwara M, Kameyama M Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem. 46:1986;288-293.
53. Smirk FH, McQueen EG (1957): Use of mecamylamine in the management of hypertension. Br Med J 422-425.
54. Stolerman IP, Goldfarb T, Fink R, Jarvik ME Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia. 28:1973;247-259.
55. Sunderland T, Molchan SE, Martinez RA, Vitiello B, Martin P Drug challenge strategies in Alzheimer's disease. A focus on the scopolamine model Becker RE, Giacobini E Alzheimer's Disease. Current Research in Early Diagnosis:1990;173-181 Taylor & Francis Publishers, New York.
56. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study Arch Gen Psychiatry. 44:1987;418-426.
57. Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, Cohen RM Pharmacologic modeling of Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 10:1986;599-610.
58. Takayama H, Majewska MD, London ED Interactions of noncompetitive inhibitors with nicotinic receptors in the rat brain. J Pharmacol Exp Ther. 253:1989;1083-1089.
59. Van Kammen DP, Murphy DL Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacolgia. 44:1975;215-224.
60. Wang S-Z, Zhu S-Z, Mash DC, El-Fakahany EE Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Molec Brain Res. 16:1992;64-70.
61. Wechsler D Wechsler Memory Scale - Revised Manual. 1987;The Psychological Corp, San Antonio, TX. Harcourt Brace, Inc.
62. Whitehouse PJ, Au KS Cholinergic receptors in aging and Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 10:1986;665-676.
63. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, Keller KJ Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
64. Zubenko GS, Moossy J, Hanin I, Martinez AJ, Rao GR, Kopp U Bilateral symmetry of cholinergic deficits in Alzheimer's disease. Arch Neurol. 45:1988;255-259.